NCT06698042

A Phase 3 Randomized, Open-label Clinical Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Coformulated WithHyaluronidase (MK-3475A) Versus Intravenous Pembrolizumab, in the First-line Treatmentof Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS 50 orGreater

This research study id comparing two ways of giving pembrolizumab (an immunotherapy drug) along with chemotherapy to patients with advanced/metastatic non–small cell lung cancer (NSCLC) whose tumors have high PD-L1 levels (50% or greater)—a marker that often predicts better response to immunotherapy. This Phase 3 trial tests whether injecting Pembrolizumab under the skin works just as well, is just as safe, and is faster and more convenient than the standard IV infusion for patients with PD-L1 high metastatic lung cancer.

Immunotherapy: The immune system helps fight cancer by sending the body's defense (immune) system to kill the cancer cells. Immunotherapy drugs target cancer cells to prevent them from multiplying and growing.

Advanced: Advanced cancer means that the cancer cells from the original tumor (primary tumor) get loose, spread by traveling through the body, and start a new tumor (metastatic tumor) somewhere else in the body.

Metastatic: cancer that has spread from its original location or organ to other parts of the body.

Non-small cell lung cancer: A type of lung cancer with non small cells that grow too much and can spread to other parts of the body

PD-L1: PD-1 is a protein found on T cells (a type of immune cell) that helps keep the body’s immune responses (defense system) in check. When this protein is blocked, the “brakes” on the immune system are released and the ability of T cells to kill cancer cells is increased.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT06698042

Clinical Trial Site: Einstein

To see all available clinical trials click here.